Schizophrenia: One Name, Many Different Manifestations
- PMID: 36402500
- DOI: 10.1016/j.mcna.2022.05.005
Schizophrenia: One Name, Many Different Manifestations
Abstract
Schizophrenia is a disabling condition impacting approximately 1% of the worldwide population. Symptoms include positive symptoms (eg, hallucinations, delusions), negative symptoms (eg, avolition, anhedonia), and cognitive impairment. There are likely many different environmental and pathophysiologic etiologies involving distinct neurotransmitters and neurocircuits. Pharmacologic treatment at present consists of dopamine receptor antagonists, which are reasonably effective at treating positive symptoms, but less effective at treating cognitive and negative symptoms. Nondopaminergic medications targeting alternative receptors are under investigation. Supportive psychosocial treatments can work in tandem with antipsychotic medications and optimize patient care.
Keywords: Antipsychotics; Dopamine; First episode psychosis; Neuropathophysiology; Psychopharmacology; Psychosis; Schizophrenia.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure J. Faden: No conflicts of interest. L. Citrome: Consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; Speaker: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; Stocks (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased greater than 10 years ago, stock options: Reviva; Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics).
Similar articles
-
Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.Int Rev Neurobiol. 2007;78:165-92. doi: 10.1016/S0074-7742(06)78006-0. Int Rev Neurobiol. 2007. PMID: 17349861 Review.
-
[A rare and not very studied disorder: childhood-onset schizophrenia. A case report].Encephale. 2004 Nov-Dec;30(6):540-7. doi: 10.1016/s0013-7006(04)95468-1. Encephale. 2004. PMID: 15738856 French.
-
[Schizophrenia: a psychobiological view].Rev Neurol. 1996 Oct;24(134):1210-20. Rev Neurol. 1996. PMID: 8983716 Review. Spanish.
-
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.CNS Spectr. 2014 Dec;19 Suppl 1:38-52; quiz 35-7, 53. doi: 10.1017/S1092852914000601. Epub 2014 Nov 18. CNS Spectr. 2014. PMID: 25403863 Review.
-
Dopamine antagonist antipsychotics in diverted forensic populations.CNS Spectr. 2020 Apr;25(2):128-135. doi: 10.1017/S1092852919000841. Epub 2019 May 7. CNS Spectr. 2020. PMID: 31060635 Review.
Cited by
-
A multicenter, double-blind, randomized, controlled study of patients with treatment-resistant schizophrenia treated with yokukansan for 12 weeks.PCN Rep. 2023 Nov 14;2(4):e155. doi: 10.1002/pcn5.155. eCollection 2023 Dec. PCN Rep. 2023. PMID: 38868736 Free PMC article.
-
The roles of extracellular vesicles in mental disorders: information carriers, biomarkers, therapeutic agents.Front Pharmacol. 2025 Apr 9;16:1591469. doi: 10.3389/fphar.2025.1591469. eCollection 2025. Front Pharmacol. 2025. PMID: 40271072 Free PMC article. Review.
-
[Ursolic acid improved demyelination and interstitial fluid drainage disorders in schizophrenia mice].Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Jun 18;56(3):487-494. doi: 10.19723/j.issn.1671-167X.2024.03.016. Beijing Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38864135 Free PMC article. Chinese.
-
Altered intrinsic neural activity and its molecular analyses in first-episode schizophrenia with auditory verbal hallucinations.Front Neurosci. 2024 Oct 29;18:1478963. doi: 10.3389/fnins.2024.1478963. eCollection 2024. Front Neurosci. 2024. PMID: 39534020 Free PMC article.
-
Exploring the Therapeutic Mechanism of Pingxin Dingzhi Decoction Through Network Pharmacology and Molecular Docking.Alpha Psychiatry. 2024 Sep 1;25(5):584-591. doi: 10.5152/alphapsychiatry.2024.241642. eCollection 2024 Sep. Alpha Psychiatry. 2024. PMID: 39553489 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical